Osteoarthritis, Knee Clinical Trial
— CoMeTOfficial title:
Injection After Arthroscopic Partial Meniscectomy
Verified date | April 2024 |
Source | The Cleveland Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Synovitis has an important role in the symptoms and progression of Osteoarthritis (OA). Inflamed synovium has been associated with both increased symptoms and increased progression in OA patients. Furthermore, synovitis observed during knee arthroscopy in our patients undergoing arthroscopic partial meniscectomy (APM) was associated with worse symptoms while adjusting for confounding factors.Therefore, a better understanding of synovitis as a predictor of outcome after APM and as a target for treatment is needed to improve outcomes in this patient population. Triamcinolone has been shown to decrease synovitis-associated outcomes in both animal and human studies after anterior cruciate ligament (ACL) injury. In a porcine model of ACL injury, treatment with triamcinolone resulted in decreased formation of synovitis-related collagen breakdown products as well as decreased cellularity of the synovium.And in a trial of triamcinolone injected after ACL injury, similar findings of decreased C-telopeptide of type II collagen (CTX-II), associated with collagen type II breakdown, was found in knees administered triamcinolone compared to placebo controls.
Status | Enrolling by invitation |
Enrollment | 150 |
Est. completion date | May 1, 2025 |
Est. primary completion date | March 22, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: 1. Male or female age 40 and older 2. Scheduled for APM with enrolling surgeon 3. Arthroscopic evidence of structural OA including at least one surface with grade 2 chondral change 4. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study. Exclusion Criteria: 1. Females who are pregnant or nursing or plan to become pregnant during the study; men who plan to inseminate a partner or donate sperm 2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. 3. Known or suspected hypersensitivity to Zilretta (or component of Zilretta) or triamcinolone acetonide 4. Kellgren and Lawrence Grade IV (severe OA; arthroplasty is typically preferred over APM in this setting) 5. Injection with corticosteroid into affected knee in past 12 weeks 6. Injection with platelet rich plasma into affected knee in past 12 weeks 7. Injection with hyaluronic acid into affected knee in past 24 weeks 8. Plan for cartilage resurfacing procedure (microfracture, autologous chondrocyte implantation, osteochondral autograft or allograft), ligament reconstruction or other open procedure 9. Bilateral surgery 10. Unable to undergo MRI due to implanted medical device, aneurysm clamp, metal fragments in eye, etc. 11. Absence of at least one area of grade 2 chondral change on diagnostic arthroscopy (patients without structural OA are excluded) |
Country | Name | City | State |
---|---|---|---|
United States | Bringham and Women's Hospital | Boston | Massachusetts |
United States | Cleveland Clinic Foundation | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
The Cleveland Clinic | Arthritis Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Knee injury and Osteoarthritis Outcome Score (KOOS) from baseline and 3 months. | Knee pain of participants; a higher score represents a desired outcome; zero representing extreme knee problems and 100 representing no knee problems | 0 and 3 months | |
Secondary | Change in Knee injury and Osteoarthritis Outcome Score (KOOS) from baseline, 6 and 12 months. | Knee pain of participants; a higher score represents a desired outcome; zero representing extreme knee problems and 100 representing no knee problems | 0, 6, and 12 months | |
Secondary | Change in Inflammatory biomarkers in circulation from baseline, 3 and 12 months. | Urine; CTX-II | 0, 3, and 12 months | |
Secondary | Change in Inflammatory biomarkers of the knee joint from baseline, 3, and 12 months. | The increase or decrease from the combination of following markers in the Synovial fluid will help characterize the profile of knee joint; TGF-ß1, neutrophil elastase, IL-1, IL-6, IL-8, TNF, MCP-1, MIP1, MMP-3, MMP-10, MMP activity, sGAG, aggrecanase, TIMP-1, and PGE2 | 0, 3, and 12 months | |
Secondary | Change in Inflammatory biomarkers in circulation from baseline, 3 and 12 months. | The increase or decrease from the combination of the following markers in the serum will help characterize the inflammatory profile of the individual systemically; hyaluronic acid, IL-1, IL-6, IL-8, TNF, TIMP-1, MMP-10, MCP-1, MIP1, and PGE2 | 0, 3 and 12 months | |
Secondary | Change in Magnetic Resonance Imaging relaxation time (milliseconds of T1 and T2) from baseline, 3, and 12 months. | Quantitative measurement of cartilage, longer relaxation time represents a poor outcome | 0, 3 and 12 months | |
Secondary | Change in Whole-Organ Magnetic Resonance Imaging Score (WORMS) from baseline, 3, and 12 months. | Bone shape, a higher score represents a poor outcome; zero representing no knee problems and 332 representing knee problems | 0, 3 and 12 months | |
Secondary | Change in Magnetic Resonance Imaging morphological grading from baseline, 3, and 12 months. | Modified MRI Osteoarthritis Knee Score (MOAKS); a higher score represents a poor outcome; zero representing no knee problems and 332 representing knee problems | 0, 3 and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03895489 -
Effectiveness of the Journey Total Knee Arthroplasty Versus Two Standard of Care Total Knee Arthroplasty Prostheses
|
N/A | |
Completed |
NCT03660943 -
A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain
|
Phase 3 | |
Completed |
NCT04531969 -
Comparison of Outpatient and Inpatient Spa Therapy
|
N/A | |
Completed |
NCT02848027 -
Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment
|
Phase 3 | |
Completed |
NCT05160246 -
The Instant Effect of Kinesiology Taping in Patients With Knee OA
|
N/A | |
Recruiting |
NCT06080763 -
Biomechanics and Clinical Outcomes in Responders and Non-Responders
|
||
Completed |
NCT03643588 -
The Comparison of HYAJOINT Plus and Hyalgan Hyaluronan Supplement for Knee Osteoarthritis Pain
|
N/A | |
Active, not recruiting |
NCT05100225 -
Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis
|
Phase 2 | |
Active, not recruiting |
NCT04061733 -
New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis
|
N/A | |
Completed |
NCT04051489 -
A Novel Smartphone Application for "Smart" Knee Osteoarthritis Trials
|
||
Recruiting |
NCT05546541 -
Epidemiology and Nutrition
|
||
Recruiting |
NCT05447767 -
Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg
|
Phase 2 | |
Not yet recruiting |
NCT04448106 -
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
|
Phase 2 | |
Not yet recruiting |
NCT03225911 -
Effect of a Lateral Wedge Insole and Simple Knee Sleeve in Individuals With Knee Osteoarthritis
|
N/A | |
Completed |
NCT05070871 -
A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women
|
N/A | |
Completed |
NCT05703087 -
Positive Cueing in Knee Arthroplasty.
|
N/A | |
Not yet recruiting |
NCT06042426 -
Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population
|
Phase 4 | |
Completed |
NCT02901964 -
Effect of Strengthening the Hip Abductor in Patients With Knee Osteoarthritis: Randomized Controlled Trial
|
N/A | |
Completed |
NCT02944448 -
A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee
|
Phase 2 | |
Not yet recruiting |
NCT02826850 -
Saphenous Nerve Radiofrequency for Knee Osteoarthritis Trial
|
Phase 3 |